tbo filgrastim
Jump to navigation
Jump to search
Introduction
See filgrastim
Indications
- attenuation of chemotherapy-induced neutropenia
Dosage
- administered as an injection beginning 24 hours after chemotherapy treatment
Adverse effects
Mechanism of action
- stimulates bone marrow production of neutrophils
Notes
- FDA has not approved tbo-filgrastim as a biosimilar to Neupogen (filgrastim)
More general terms
References
- ↑ FDA News Release: Aug. 29, 2012 FDA approves new treatment for severe neutropenia in certain cancer patients http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm